RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: LL1500 for IBS-D (Diarrhea-predominant)

The goal of this clinical trial is to learn whether a probiotic supplement can improve symptoms and quality of life in adults with diarrhea-predominant irritable bowel syndrome (IBS-D) or functional diarrhea (FD). These conditions can cause frequent loose stools, abdominal discomfort, and a lower quality of life.

Official registry: https://clinicaltrials.gov/study/NCT07916688 · Szeged University · enrollment listed as 100

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are LL1500, or Placebo Capsule. The registry lists allocation as randomized. The goal of this clinical trial is to learn whether a probiotic supplement can improve symptoms and quality of life in adults with diarrhea-predominant irritable bowel syndrome (IBS-D) or functional diarrhea (FD).

They plan to enroll about 100 people at Szeged. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

Efficacy of Lactic Acid Bacteria in Managing Diarrhea-Associated Functional Gastrointestinal Disorders: A Randomized Controlled Trial

Interventions: LL1500, Placebo Capsule

Primary outcome (registry wording): Irritable Bowel Syndrome Quality of Life (IBS-QOL) Total Score at 3 Months

Who it is for (from inclusion criteria)

Ages 18 Years to any
Adults aged 18 years or older
Have diarrhea-predominant irritable bowel syndrome (IBS-D) or functional diarrhea (FD) diagnosed using Rome V criteria
Have had symptoms for at least 6 months
Have no warning signs that suggest another digestive disease
Have been taking the same treatment for IBS-D, FD, and other medical conditions for at least 1 month before joining the study

Who the registry excludes

Took antibiotics or probiotic products within the past 4 weeks
Had abdominal surgery in the past, except appendix removal (appendectomy)
Have another type of irritable bowel syndrome or another functional digestive disorder
Have a known digestive disease that may explain their symptoms
Plan to start a new medication or change the dose of an existing medication during the study (except antispasmodic medications)
Are unable or unwilling to complete study questionnaires and daily symptom records

Public study contact (from the registry)

Tamás Molnár

+36-62-545-189

molnar.tamas@med.u-szeged.hu

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

University of Szeged — Szeged, Hungary (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseLeuven, Vlaams-Brabant

Not a traditional drug phase: Sample collection for IBS

Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.

NCT02421705 · Official ClinicalTrials.gov record · KU Leuven

RecruitingNot a traditional drug phaseRochester, Minnesota

Mucosal and Microbiota Changes During Acute Campylobacteriosis

Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS).

NCT03223077 · Official ClinicalTrials.gov record · Mayo Clinic

RecruitingPhase 2 / Phase 3Ann Arbor, Michigan

Phase 2 / Phase 3: testing Lexapro for Irritable Bowel Syndrome With Constipation

This study will assess the how well it works of two active treatments with TEA and a chemical neuromodulator (escitalopram aka Lexapro) versus a sham comparator or control group on abdominal pain.

NCT05519683 · Official ClinicalTrials.gov record · University of Michigan

FAQ about this NCT record

Is NCT07916688 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07916688?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07916688?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary